| Trial ID: | L2702 |
| Source ID: | NCT06095492
|
| Associated Drug: |
Empagliflozin 25 Mg
|
| Title: |
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
|
| Acronym: |
EmLinaRenal
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Kidney Transplant; Complications|Diabetes Mellitus
|
| Interventions: |
DRUG: Empagliflozin 25 MG|DRUG: Linagliptin
|
| Outcome Measures: |
Primary: Estimated glomerular filtration rate (eGFR), Basline to 12 Months|Spot urine albumin- creatinine ratio, Basline to 12 Months|Spot urine protein-creatinine ratio, Basline to 12 Months | Secondary: Changes in total fat content, Measured by DEXA \& BIA, Basline to 12 Months|Changes in fat percentage, Measured by DEXA \& BIA, Basline to 12 Months|Changes in lean mass, Measured by DEXA \& BIA, Basline to 12 Months|Changes in bone mineral content, Measured by DEXA \& BIA, Basline to 12 Months|Changes in fasting glucose, Basline to 12 Months|Changes in HbA1c, Basline to 12 Months
|
| Sponsor/Collaborators: |
Sponsor: Medanta, The Medicity, India
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
200
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-10-30
|
| Completion Date: |
2025-12-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-05
|
| Locations: |
Division Of Endocrinology & Diabetes, Medanta The Medicity, Gurgaon, Haryana, 122001, India
|
| URL: |
https://clinicaltrials.gov/show/NCT06095492
|
